Internal marketing documents from Eli Lilly indicate the drugmaker encouraged doctors to prescribe Zyprexa, a drug for schizophrenia and bipolar disorder, to patients who had neither condition, The New York Times says. The files say Lilly began the Viva Zyprexa campaign in late 2000 and told sales representatives to encourage doctors to prescribe the drug for older patients with dementia symptoms. A Lilly executive says the company has never promoted Zyprexa for off-label use and always shows marketing materials to the FDA.

Full Story:

Related Summaries